Oramed Pharmaceuticals Inc. Begins Additions to an Advisory Board
JERUSALEM, April 10 /PRNewswire-FirstCall/ -- Oramed Pharmaceuticals, Inc is proud to announce the addition of Dr. Harold Jacob to its advisory board.
Dr. Harold Jacob has a strong background, both in medical sciences as well as biotechnology and medical devices. He practiced clinical gastroenterology in New York and served as Chief of Gastroenterology at St. Johns Episcopal Hospital and South Nassau Communities Hospital, and was a Clinical Assistant Professor of Medicine at SUNY. Dr. Jacob founded and served as Editor in Chief of Endoscopy Review and has authored numerous publications in the field of gastroenterology.
Dr. Jacob is president of Medical Instrument Development Inc., which is a company which provides a range of support and consulting services to start-up and early stage companies as well as patenting it's own proprietary medical devices and biologicals. He has advised a spectrum of companies including Med-Dynamix Ltd., Ballard Medical, The BioBalance Corporation, as well as others. He served as a consultant and then as the Director of Medical Affairs at Given Imaging Ltd., which is the company that developed the first swallowable wireless pill camera for inspection of the intestine. He has licensed patents to a number of companies including Kimberly Clark Ballard. Dr. Jacob is presently CEO of NanoVibronix, a medical device company using surface acoustics to prevent catheter acquired infection as well as other applications.
CEO Nadav Kidron states, "We are honored to have Dr. Harold Jacob advise us, and look forward to working with him to complete development of the our oral insulin, which will simplify the lives of millions of diabetics and realize the immense growth potential that Oramed holds."
About Oramed Pharmaceuticals, Inc:Oramed Pharmaceuticals' is an Israeli based company focused on the development of oral delivery solutions based on proprietary technology. Diabetes is one of the most rapidly growing diseases in the world and is one that requires constant and often unpleasant monitoring and drug therapy regimen. Oramed is currently developing an orally soft gel insulin capsule for the treatment of diabetes. The Company is also pursuing the development of oral delivery solutions for other drugs and vaccines.
For more information on Oramed Pharmaceuticals please visit our website: www.oramedpharma.com
Investor Relations Contact: Oramed Pharmaceuticals, Inc. Vinisha Agnihotri (646) 467-2252 info@oramedpharma.comwww.oramedpharma.com
Oramed Pharmaceuticals, Inc.CONTACT: Vinisha Agnihotri, Oramed Pharmaceuticals, Inc., +1-646-467-2252,or info@oramedpharma.com
Web site: http://www.oramedpharma.com/